Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, comparative, phase II/III study to evaluate the immunogenicity and safety of three formulations (15mcg without adjuvant and 7.5mcg with adjuvant and 3.75mcg with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults. - H1N1 Adult

Trial Profile

A randomized, double blind, comparative, phase II/III study to evaluate the immunogenicity and safety of three formulations (15mcg without adjuvant and 7.5mcg with adjuvant and 3.75mcg with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults. - H1N1 Adult

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Panacea Biotec

Most Recent Events

  • 21 Aug 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top